General
Preferred name
MAGNESIUM CHLORIDE
Synonyms
MgCl2 ()
P&D ID
PD051435
CAS
12285-34-6
7786-30-3
Tags
inorganic
nuisance
drug
available
Drug Status
approved
Max Phase
Phase 4
Drug indication
Replenisher (electrolyte)
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA Mechanism of action of magnesium chloride studied in 10 adult volunteers. Results suggested magnesium ion in duodenum is relatively weak stimulus to pancreas and gall bladder. It is weak stimulant to cholecystokinin release and inhibits net jejunal water absorption.; The oral administration of a single 800 mg dose of magnesium chloride in healthy volunteers resulted in a diminished rate of intraluminal lipid and protein digestion. The most pronounced effect of magnesium chloride, however, was a decreased gastric emptying rate of both test meals. After correction for gastric emptying, no differences were noted in intraluminal lipid or protein digestion. Therefore, the lower lipid levels noted after magnesium supplementation are unlikely to be the result of altered lipid assimilation. Magnesium chloride slows gastric emptying but does not influence lipid digestion.
INDICATION Magnesium chloride is used in several medical and topical (skin related) applications. Magnesium chloride usp, anhydrous uses as electrolyte replenisher, pharmaceutic necessity for hemodialysis and peritoneal dialysis fluids.;
TOXICITY Mouse LD50 775mg/kg (intraperitoneal); Mouse LD50 : 7600mg/kg (oral); Rat LD 50 : 8100mg/kg (oral); Rat LD50 176mg/kg (intravenous); Severe toxicity occurs most often after intravenous infusions. It can also occur after chronic excessive oral doses, often in patients with renal insufficiency. Early manifestations are lethargy, hyporeflexia, followed by weakness, paralysis, hypotension, ECG changes (prolonged PR and QRS intervals), CNS depression, seizures, and respiratory depression. In overdose, magnesium impairs neuromuscular transmission, manifested as weakness and hyporeflexia.
HALF-LIFE Elimination half-life has been reported to be 27.7 hours following an overdose of 400 mEq magnesium in an adult.;
Compound Sets
8
ChEMBL Approved Drugs
CHEMBL2219642
ChEMBL Drugs
CHEMBL2219642
DrugBank
DB09407
DrugBank Approved Drugs
DB09407
Ki Database
MgCl2
Nuisance compounds in cellular assays
ReFrame library
Selleckchem Bioactive Compound Library
magnesium-chloride
External IDs
29
Properties
(calculated by RDKit )
Molecular Weight
93.92
Hydrogen Bond Acceptors
0
Hydrogen Bond Donors
0
Rotatable Bonds
0
Ring Count
0
Aromatic Ring Count
0
cLogP
-6.37
TPSA
0.0
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
0.0
QED
0.26
Structural alerts
1
Metal impurity
Nuisance compounds in cellular assays
Custom attributes
(extracted from source data)
Source data